Trial Profile
A Randomized Phase III Study of Decitabine (DAC) With or Without Hydroxyurea (HY) Versus HY in Patients With Advanced Proliferative Chronic Myelomonocytic Leukemia (CMML)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Dec 2022
Price :
$35
*
At a glance
- Drugs Decitabine (Primary) ; Hydroxycarbamide
- Indications Chronic myelomonocytic leukaemia
- Focus Therapeutic Use
- Acronyms DACOTA
- 01 Dec 2022 Results published in the Journal of Clinical Oncology
- 17 Nov 2021 Status changed from active, no longer recruiting to completed.
- 17 Nov 2021 This trial has been completed in Germany (End Date: 16 Aug 2021), according to European Clinical Trials Database record.